Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study https://doi.org/10.5414/CP203861 73 patients were divided into two groups: group LR (34 cases) and group LR+Ar (39 cases), according to the antiviral… Continue reading "(25 Feb 2021) Lopinavir/r & Arbidol- did not significantly accelerate main symptom improvement"
Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial https://doi.org/10.1186/s12879-020-05698-w TRIAL REGISTRATION: IRCT20180725040596N2 , The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across… Continue reading "(16 Dec 2020) Umifenovir- significant improvement in Clinical outcomes compared to KALETRA"
Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series https://doi.org/10.1186/s12985-020-01428-5 In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient’s conditions. Arbidol… Continue reading "(25 Oct 2020) Arbidol- showed beneficial effects on fever recovery, viral clearance and shorter hospital stay in males"
Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals https://doi.org/10.3389/fpubh.2020.00249 A total of 164 subjects were included in this study, 82 cases in the infected group and 82 controls in the uninfected group, with a median age of 37 years,… Continue reading "(24 June 2020) Arbidol- Prophylactic arbidol proved to be protective against COVID-19 in health professionals"
A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19 https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26142 The study included 62 patients with COVID-19 admitted to the First Hospital of Jiaxing from January to March, 2020, and all patients were divided into the… Continue reading "(09 June 2020) Arbidol- combined with adjuvant therapy could normalize patient’s temperature faster"
Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study https://doi.org/10.1016/j.micinf.2020.05.012 This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged… Continue reading "(24 May 2020) Arbidol- Arbidol/IFN-α2b combination did not accelerate virus clearance"
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. https://doi.org/10.1016/j.jinf.2020.03.002 In this retrospective cohort study, 16 patients received oral arbidol and LPV/r in the combination group and 17 received oral LPV/r only in… Continue reading "(16 May 2020) Arbidol-favorable clinical response when arbidol is combined with LPV/r"
Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study https://doi.org/10.1016/j.cmi.2020.04.026 In a retrospective study, 81 COVID-19 patients were included, with 45 in the umifenovir group and 36 in the control group. Baseline… Continue reading "(29 April 2020)- Umifenovir- did not shorten the negativity time of SARS-CoV-2 in non ICU patients"
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 https://www.journalofinfection.com/article/S0163-4453(20)30188-2/pdf In the present study, the authors anayzed the efficacy and safety of lopinavir/ritonavir and arbidol monotherapy in patients with COVID-19. On day 14 after the admission, no viral load was… Continue reading "(14 April 2020)- Umifenovir (Arbidol)- shorter duration of positive RNA test"
